Insurance Coverage Assessment for Pre-IPO Companies: D&O Liability and Key Person Insurance

The Hong Kong Stock Exchange’s (HKEX) December 2024 consultation on proposed enhancements to the Listing Rules regarding corporate governance and risk management has placed a renewed spotlight on the adequacy of pre-IPO insurance arrangements, particularly for companies targeting a Main Board listing in 2025-2026. The consultation paper, which proposes amendments to the Corporate Governance Code (CG Code) and related Listing Rules, explicitly calls for enhanced board oversight of risk management and internal controls, including the identification and mitigation of emerging risks such as cybersecurity and climate-related liabilities. This regulatory push coincides with a hardening global insurance market for Directors’ & Officers’ (D&O) liability, where premiums for Hong Kong-listed small-caps and pre-IPO issuers have risen by an estimated 15-25% year-on-year since 2023, according to broker surveys. For a pre-IPO company, the failure to secure appropriate D&O and Key Person insurance before filing an A1 application not only exposes its board to personal liability but can become a material deficiency flagged by the Listing Division during its vetting process, directly impacting the timeline and valuation of the offering. The cost of such insurance, while non-trivial, is a fraction of the potential litigation and reputational damage from a single regulatory action or shareholder class-action suit post-listing.

The Regulatory Imperative: Aligning Insurance Coverage with the CG Code and Listing Rules

The foundation for any pre-IPO insurance assessment lies in the mandatory disclosure requirements under the HKEX Listing Rules and the principles-based CG Code. A pre-IPO company’s board must demonstrate that its risk management framework, including insurance coverage, is commensurate with the scale and complexity of its business. This is not a voluntary exercise; it is a pre-condition for listing approval.

The CG Code’s Explicit Requirement for Risk Oversight

The current CG Code, specifically Code Provision D.2.1, requires the board to oversee the company’s risk management and internal control systems on an ongoing basis. The proposed 2024 amendments, if enacted, would elevate this to a mandatory disclosure requirement. The board must document how it has identified principal risks, including those specific to the directors and key executives. A failure to maintain D&O insurance with adequate aggregate limits (typically HKD 50-200 million for a mid-cap Main Board candidate) is a direct indicator of insufficient risk mitigation. The Listing Division, in its review of the prospectus, will scrutinise the “Risk Factors” section and the Corporate Governance Report. If the company discloses no D&O insurance or a policy with a sub-optimal retention (self-insured retention, or SIR) that is too high relative to the company’s net profit, it raises a red flag.

The A1 Filing and the Prospectus Disclosure Obligation

Under the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) and the Listing Rules, the prospectus must contain “all information necessary to enable a reasonable investor to make an informed assessment of the company’s financial position and prospects.” This implicitly covers material liabilities, including potential D&O claims. A pre-IPO company should, in its draft prospectus submitted with the A1 application, disclose the existence and key terms of its D&O insurance policy. This includes the aggregate limit, the SIR, and the scope of coverage (e.g., whether it covers securities claims, regulatory investigations, and derivative actions). The SFC’s Code of Conduct for Persons Licensed by or Registered with the SFC (the “Code of Conduct”) also places a duty on sponsors (the 保薦人) to conduct reasonable due diligence on the company’s risk profile. A sponsor that fails to identify a gap in D&O coverage could itself face regulatory action.

The Mechanics of D&O Liability Insurance for Pre-IPO Entities

D&O insurance for a pre-IPO company is structurally distinct from a post-listing policy. The key difference lies in the “run-off” period and the definition of a “claim” in the context of the initial public offering (IPO) process itself.

Side A, B, and C Coverage: The Pre-IPO Nuance

Standard D&O policies have three insuring clauses. Side A covers directors and officers when the company cannot indemnify them (e.g., due to insolvency or statutory prohibition). Side B covers the company when it indemnifies its directors. Side C, or Entity Coverage, covers the company itself for securities claims. For a pre-IPO company, Side C is critical because the majority of securities class-action claims post-listing are brought against the issuer, not just the individual directors. The policy must be structured to respond to claims arising from the IPO prospectus, including alleged misstatements or omissions. A common mistake is to purchase a policy that excludes “IPO-related claims” or has a broad “prior acts” exclusion that captures the pre-listing period. The policy must be a “claims-made” policy with a retroactive date that covers the entire period from incorporation to listing, typically three to five years prior.

The “Run-Off” Period and the Listing Date Trigger

The insurance coverage must be structured to provide a seamless transition from a private company policy to a public company policy. The standard approach is to purchase a “binder” policy that takes effect on the date the listing application is filed (the A1 date) and runs for 12 months. However, the critical trigger is the listing date. Many policies have a “listing date” definition that must be carefully worded. If the listing is delayed or cancelled, the policy must automatically extend. Furthermore, a “run-off” or “tail” policy of at least six years is standard for a Hong Kong-listed company, covering claims made after a director resigns. The cost of this tail policy should be factored into the pre-IPO budget. A typical run-off premium is 150-200% of the annual premium for a six-year tail.

The Self-Insured Retention (SIR) and Its Impact on the Balance Sheet

The SIR is the amount the company pays before the insurance policy responds. For a pre-IPO company with limited liquidity, a high SIR (e.g., HKD 5-10 million) is financially imprudent. It creates a contingent liability that must be disclosed in the prospectus. The Listing Division and the SFC will assess whether the company has sufficient working capital to meet the SIR in the event of a claim. A prudent approach is to set the SIR at a level that is no more than 1-2% of the company’s net profit for the most recent financial year, as disclosed in the profit forecast or historical financials. A higher SIR may be acceptable if the company has a strong cash position, but it must be justified in the “Risk Factors” section.

Key Person Insurance: Protecting the IPO Valuation and Post-Listing Stability

Key Person insurance is a life or disability policy on the founder, CEO, or chief technology officer (CTO). While not a mandatory requirement under the Listing Rules, its absence is a material risk factor that can depress the IPO valuation. The rationale is straightforward: the company’s future earnings are heavily dependent on the continued service of one or two individuals.

The Valuation Link: Discounting for Key Person Risk

Investment banks and cornerstone investors will apply a “key person discount” to the IPO valuation if the company has no Key Person insurance in place. This discount can range from 5% to 15% of the pre-money valuation, depending on the industry (e.g., higher for biotech or fintech). The insurance policy provides a cash payout to the company upon the death or total permanent disability of the insured individual. This payout is used to cover the cost of recruiting a replacement, paying severance, and stabilising the business. The policy’s death benefit should be set at a multiple of the key person’s annual compensation plus the estimated cost of a replacement search. A common benchmark is 5-10 times annual salary, but for a pre-IPO company, the benefit should be linked to the company’s projected revenue or market capitalisation. For example, a biotech company with a pre-money valuation of HKD 500 million might purchase a HKD 100 million Key Person policy on its lead scientist.

The Underwriting Challenge: Medical and Financial Due Diligence

Insurers underwrite Key Person policies with rigorous medical and financial due diligence. For a pre-IPO company, the financial due diligence is particularly intense. The insurer will require the company’s audited financial statements, the profit forecast (if any), and a business plan. The medical underwriting for the key person is also thorough, including blood tests, ECG, and a full medical history. A pre-IPO company should start this process at least six months before the intended A1 filing date. A delay in underwriting can push back the listing timetable. The policy must be a “non-cancellable” and “guaranteed renewable” policy to ensure coverage does not lapse during the IPO process.

The Trust Structure and Beneficiary Designation

The policy must be structured as a “key person” policy, meaning the company is the owner, beneficiary, and premium payer. The proceeds are paid to the company, not to the individual or their estate. This is a critical distinction from a personal life insurance policy. The policy should be held in trust for the company to ensure the proceeds are not subject to claims from the individual’s creditors. The trust deed must be reviewed by the company’s legal counsel to ensure it complies with the Insurance Ordinance (Cap. 41) and does not create a conflict of interest for the directors.

The Cost-Benefit Analysis: Premiums, Limits, and the Listing Timeline

The cost of D&O and Key Person insurance is a direct expense that impacts the pre-IPO profit forecast. The decision to purchase adequate coverage is a trade-off between a known, quantifiable premium and an unknown, potentially catastrophic litigation risk.

Benchmarking Premiums for a Hong Kong Main Board Listing

For a Hong Kong Main Board candidate with a market capitalisation of HKD 1-5 billion, the annual D&O premium typically ranges from HKD 500,000 to HKD 2 million for an aggregate limit of HKD 50-100 million. For a larger issuer (HKD 5-20 billion market cap), the premium can exceed HKD 5 million annually. Key Person insurance premiums are driven by age and health. For a 45-year-old founder in good health, a HKD 50 million policy might cost HKD 150,000-300,000 per year. These costs are deductible as a business expense under the Inland Revenue Ordinance (Cap. 112), reducing the effective cost by the applicable profits tax rate (16.5% in Hong Kong).

The Impact of the SFC’s Enforcement Actions on Underwriting

The SFC’s increased enforcement actions against listed companies and their directors, as evidenced by the 2023-2024 annual reports, have hardened the insurance market. Insurers are now more closely scrutinising the company’s corporate governance history, including any prior regulatory actions by the SFC, the Hong Kong Monetary Authority (HKMA), or the Securities and Futures Appeals Tribunal (SFAT). A pre-IPO company with a history of non-compliance, even if minor, will face higher premiums, broader exclusions, or outright declination. The underwriter will also assess the company’s industry. Fintech, biotech, and cryptocurrency-related companies face the highest premiums due to the inherent regulatory and business model risks.

The “No-Claims” Discount and the Post-Listing Renewal

A pre-IPO company that maintains a clean claims record during the 12-24 months before listing will secure a “no-claims” discount on its post-listing renewal. This discount can be 10-20% of the premium. Conversely, a pre-IPO company that faces a claim or a regulatory investigation during the listing process will find it nearly impossible to secure affordable coverage post-listing. The listing itself is a “material change” that must be disclosed to the insurer. The company must notify the insurer of the listing, and the insurer may adjust the premium or terms. A failure to do so could void the policy.

Actionable Takeaways

1. Secure D&O coverage with a Side C entity coverage clause and a retroactive date that covers the full period from incorporation to listing, at least six months before the A1 filing, to avoid a gap in coverage that the Listing Division will flag.
2. Set the D&O policy’s aggregate limit at no less than 10% of the company’s projected post-IPO market capitalisation, and ensure the self-insured retention does not exceed 1% of the company’s net profit for the most recent financial year.
3. Purchase a Key Person insurance policy on the founder or CEO with a death benefit equal to 5-10 times their annual compensation, and hold the policy in trust for the company to ensure proceeds are not diverted.
4. Commence the insurance underwriting process for both D&O and Key Person policies at least nine months before the intended A1 filing date to accommodate the insurer’s medical and financial due diligence.
5. Disclose the existence, aggregate limit, and self-insured retention of the D&O policy in the prospectus, and ensure the sponsor confirms in its due diligence report that the coverage is adequate for the company’s risk profile.